Evaluation of Emotional Adverse Effects of Antidepressants: A Follow-up Study
- PMID: 33065720
- DOI: 10.1097/JCP.0000000000001300
Evaluation of Emotional Adverse Effects of Antidepressants: A Follow-up Study
Abstract
Purpose/background: Emotional adverse effects due to antidepressant use may cause difficulties for the clinician in the treatment of depression. In this prospective study, the emotional adverse effects of antidepressants were evaluated in various aspects.
Methods/procedures: Ninety eight patients diagnosed with major depressive disorder were included in the study. At 2nd, 4th, 8th, 12th, and 16th weeks, patients were assessed with Montgomery-Asberg Depression Rating Scale (MADRS), and the antidepressant dose was increased in patients with less than a 50% reduction at each visit compared with the initial MADRS score. The Oxford Questionnaire on the Emotional Side-effects of Antidepressants (OQESA) was used at the 8th-week and 16th-week visits.
Findings/results: A significant difference is found in the OQESA score at the 8th-week visit compared with the 16th-week assessment (P < 0.001, t = 5.73). There were significant correlations between MADRS scores and OQESA scores both at the 8th (r = 0.346, P = 0.05) and the 16th (r = 0.490, P < 0.001) weeks. In regression analyses, at eighth-week assessment, MADRS score (B = 1.487, P = 0.002) and selective serotonin reuptake inhibitor use (B = 14.014, P = 0.023) had a significantly predicted OQESA score.
Implications/conclusions: In this study, it is found that, as the rate of remitted patients is increased, OQESA scores get decreased, and furthermore, the OQESA score of the remitted group is statistically low when compared with that of the nonremitted group at the 8th- and 16th-week visits. Oxford Questionnaire on the Emotional Side-effects of Antidepressants and MADRS scores are significantly correlated in all assessments. These results suggest that the score obtained from OQESA may be related not only to the emotional adverse effects of antidepressants but also to the residual symptoms of depression.
Similar articles
-
Emotional blunting with antidepressant treatments: A survey among depressed patients.J Affect Disord. 2017 Oct 15;221:31-35. doi: 10.1016/j.jad.2017.05.048. Epub 2017 Jun 6. J Affect Disord. 2017. PMID: 28628765
-
Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: A randomized, parallel, open-label clinical study.Indian J Pharmacol. 2020 Mar-Apr;52(2):79-85. doi: 10.4103/ijp.IJP_441_18. Epub 2020 Jun 3. Indian J Pharmacol. 2020. PMID: 32565594 Free PMC article. Clinical Trial.
-
Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.Psychol Med. 2016 Feb;46(3):623-35. doi: 10.1017/S0033291715002159. Epub 2015 Oct 19. Psychol Med. 2016. PMID: 26478208 Clinical Trial.
-
Novel Augmentation Strategies in Major Depression.Dan Med J. 2017 Apr;64(4):B5338. Dan Med J. 2017. PMID: 28385173 Review.
-
Can antidepressant use be associated with emotional blunting in a subset of patients with depression? A scoping review of available literature.Hum Psychopharmacol. 2023 Jul;38(4):e2871. doi: 10.1002/hup.2871. Epub 2023 May 15. Hum Psychopharmacol. 2023. PMID: 37184083
Cited by
-
Assessing Reliability and Validity of the Oxford Depression Questionnaire (ODQ) in a Japanese Clinical Population.Neuropsychiatr Dis Treat. 2023 Nov 8;19:2401-2412. doi: 10.2147/NDT.S428443. eCollection 2023. Neuropsychiatr Dis Treat. 2023. PMID: 38029050 Free PMC article.
-
Emotional Blunting in Depression in the PREDDICT Clinical Trial: Inflammation-Stratified Augmentation of Vortioxetine With Celecoxib.Int J Neuropsychopharmacol. 2024 Mar 1;27(3):pyad066. doi: 10.1093/ijnp/pyad066. Int J Neuropsychopharmacol. 2024. PMID: 38441216 Free PMC article. Clinical Trial.
-
The Role of Vortioxetine in the Treatment of Depressive Symptoms in General Hospital Psychiatry: A Case-Series and PRISMA-Compliant Systematic Review of the Literature.J Clin Med. 2024 Jan 17;13(2):531. doi: 10.3390/jcm13020531. J Clin Med. 2024. PMID: 38256665 Free PMC article. Review.
References
-
- Opbroek A, Delgado PL, Laukes C, et al. Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses?Int J Neuropsychopharmacol. 2002;5:147–151.
-
- Price J, Cole V, Goodwin GM. Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study. Br J Psychiatry. 2009;195:211–217.
-
- Sansone RA, Sansone LA. SSRI-induced indifference. Psychiatry (Edgmont). 2010;7:14–18.
-
- Goodwin GM, Price J, De Bodinat C, et al. Emotional blunting with antidepressant treatments: a survey among depressed patients. J Affect Disord. 2017;221:31–35.
-
- Price J, Goodwin GM. Emotional blunting or reduced reactivity following remission of major depression. Medicographia. 2009;31:152–156.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical